Litcius/Paper detail

Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study

Andrew Blauvelt, Kim Papp, Joseph F. Merola, Alice B. Gottlieb, Nancy Cross, Cynthia Madden, Maggie Haitian Wang, Christopher L. Cioffi, C.E.M. Griffiths

2020Journal of the American Academy of Dermatology61 citationsDOI

Topics & Concepts

MedicineDouble blindedPlaceboPlaque psoriasisRandomized controlled trialBlinded studyDermatologyPsoriasisPhysical therapySurgeryPathologyAlternative medicinePsoriasis: Treatment and PathogenesisSpondyloarthritis Studies and TreatmentsHidradenitis Suppurativa and Treatments
Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study | Litcius